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The evolution of drug therapy and the challenges to physicians, patients and
healthcare systems
Without doubt we are living through a singular era in the evolution of oncohematology
owing to our biological understanding of diseases and all the characteristic developments
that go with it in respect to diagnosis, prognosis and treatment. The development of drugs
with specific therapeutic targets constitutes a new stage, in many ways revolutionary, in
medical practice and oncology. This has been an important reason for the constant rise in
life expectancy related to our specialty. In some diseases, such as in chronic myeloid
leukemia and malignant lymphoma, this increase has been such that it has definitively
changed the natural evolution of illnesses by the significant increase in response rates and
complete cure. In other diseases, such as in multiple myeloma, there has been a remarkable
improvement in survival and quality of life. And there are many other examples. However,
these achievements are not easy and definitely not cost-free; this progress should always
be analyzed and sanctioned by society. Brazil certainly has one of the most advanced
legislations in terms of public health. No country in the world, as far as I know, has included
in its constitution the guarantee of universally free access to healthcare to its citizens. In
recent publications in the prestigious British journal Lancet(1,2) these facts were reported
and discussed and Brazil was highly commended for the fact that public health policies are
at the center of government decisions. We look forward to the vote in Congress on a
supplementary law known as Amendment 29, which should set percentages for healthcare
financing. We live with our day-to-day problems that range from regulation issues, with the
excessive sluggishness and bureaucracy of our system, to constant difficulties to access
new procedures and modern therapies. Of course we understand the difficulties and the
dilemma of public healthcare worldwide. However, we must always defend science and the
evidence to incorporate new diagnostic and treatment methods. This is why our Association
is developing its project of "guidelines"(3) and aims to, on issues of great importance and
complexity, make it clear to organized society, governments, the Brazilian National Health
Agency (ANS) and to whoever else is interested, our position on the state-of-the-art
technology. In the field of drug therapy, this matter is very complex and troubling. We see
a huge delay in the incorporation of new therapeutic methods with clear and unacceptable
harm to our patients, not to mention the embarrassment that this fact causes doctors and
institutions. Brazil is experiencing a time of accelerated progress and increased wealth that
places us as one of the emerging countries heading towards the developed world. These
difficulties are not sustainable when we analyze our development. Our investment in health
is less than many poorer countries without our infrastructure.
Brazilian hematology and transfusion medicine has also been contributing to science,
education and healthcare. But it is also suffering from tremendous, often overwhelming
difficulties to accelerate and implant scientifically based procedures of absolute necessity
created by our scientific community. Thus, we warn that a new modern development policy
on oncohematology for the healthcare system focused on the unique and set interests of
patients and based on indisputable scientific criteria should prevail in our society and in
our specialty.
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